Abstract:Over the past decade, there has been growing interest in the use of antibodies against intracellular targets. This is currently achieved through recombinant expression of the single chain variable fragment (scFv) antibody format within the cell, which is commonly referred to as an intrabody. This possesses a number of inherent advantages over RNA interference (iRNA). Firstly, the high specificity and affinity of intrabodies to target antigens is well-established, whereas iRNA has been frequently shown to exert multiple non-specific effects. Secondly, intrabodies being proteins possess a much longer active half-life compared to iRNA. Thirdly, when the active half-life of the intracellular target molecule is long, gene silencing through iRNA would be slow to yield any effect, whereas the effects of intrabody expression would be almost instantaneous. Lastly, it is possible to design intrabodies to block certain binding interactions of a particular target molecule, while sparing others. There is, however, various technical challenges faced with intrabody expression through the application of recombinant DNA technology. In particular, protein conformational folding and structural stability of the newly-synthesized intrabody within the cell is affected by reducing conditions of the intracellular environment. Also, there are overwhelming safety concerns surrounding the application of transfected recombinant DNA in human clinical therapy, which is required to achieve intrabody expression within the cell. Of particular concern are the various viral-based vectors that are commonly-used in genetic manipulation. A novel approach around these problems would be to look at the possibility of fusing protein transduction domains (PTD) to scFv antibodies, to create a ‘cell-permeable’ antibody or ‘Transbody’. PTD are short peptide sequences that enable proteins to translocate across the cell membrane and be internalized within the cytosol, through atypical secretory and internalization pathways. There are a number of distinct advantages that a ‘Transbody’ would possess over conventional intrabodies expressed within the cell. For a start, ‘correct’ conformational folding and disulfide bond formation can take place prior to introduction into the target cell. More importantly, the use of cell-permeable antibodies or ‘Transbodies’ would avoid the overwhelming safety and ethical concerns surrounding the direct application of recombinant DNA technology in human clinical therapy, which is required for intrabody expression within the cell. ‘Transbodies’ introduced into the cell would possess only a limited active half-life, without resulting in any permanent genetic alteration. This would allay any safety concerns with regards to their application in human clinical therapy.

The use of intracellular single-chain antibody fragments to inhibit specifically the expression of cell surface molecules

Making cell-permeable antibodies (Transbody) through fusion of protein transduction domains (PTD) with single chain variable fragment (scFv) antibodies: Potential advantages over antibodies expressed within the intracellular environment (Intrabody)

Construction and Expression of Single-Chain Antibody Derived from a New Clone of Monoclonal Antibody Against Human CD14 in CHO Cells

[Construction and Expression of Prokaryotic Vector of Single Chain Antibody Derived from a New Clone of Anti-Cd14 Antibody ZCH-7-2F9].

Characterization Of Anti-Citrinin Specific Scfvs Selected From Non-Immunized Mouse Splenocytes By Eukaryotic Ribosome Display

Cell-free eukaryotic systems for the production, engineering, and modification of scFv antibody fragments

Soluble Expression and Purification of a Novel Single-Chain Fv Antibody Against Connective Tissue Growth Factor(ctgf/ccn2)

Production and fluorescence-activated cell sorting of Escherichia coli expressing a functional antibody fragment on the external surface.

Intrabodies against the EVH1 domain of Wiskott-Aldrich syndrome protein inhibit T cell receptor signaling in transgenic mice T cells

High-level expression and characterization of an anti-VEGF165 single-chain variable fragment (scFv) by small ubiquitin-related modifier fusion in Escherichia coli

Engineering Production of Functional Scfv Antibody in E. Coli by Co-Expressing the Molecule Chaperone Skp

Construction and Expression of Single Chain Variable Fragments (scfv) Against Human CD19 Antigen

Intrabody-Based Gene Therapeutic Strategy

Downregulation of Transferrin Receptor Surface Expression by Intracellular Antibody

Vector design for enhancing expression level and assembly of knob-into-hole based FabscFv-Fc bispecific antibodies in CHO cells

Effect of Chimeric Intron on the Expression of Anti-bFGF Antibody Genes in 293T Cells

A single-chain antibody fragment against human thyroglobulin: construction and evaluation of immunoreactivity

Expression and activity measurements of single chain Fv of anti-idiotypic antibody 3F6 against small cell lung cancer

Highly Efficient Selection of the Stable Clones Expressing Antibody–il-2 Fusion Protein by a Dicistronic Expression Vector Containing a Mutant Neo Gene

A generic strategy for subcloning antibody variable regions from the scFv phage display vector pCANTAB 5 E into pASK85 permits the economical production of F(ab) fragments and leads to improved recombinant immunoglobulin stability

A novel and efficient route for the isolation of antibodies that recognise T cell receptor V alpha(s)